Christopher Mutz
Corporate Officer/Principal bei ANI PHARMACEUTICALS, INC.
Vermögen: 5 Mio $ am 30.04.2024
Profil
Christopher K.
Mutz is currently the Senior Vice President & Head-Rare Diseases at ANI Pharmaceuticals, Inc. Previously, he worked as the National Sales Director-US Metabolic Business Unit at Alexion Pharmaceuticals, Inc. He completed his undergraduate degree at the University of Virginia and holds an MBA from the Johnson Graduate School of Management.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 21.05.2024 | 83 277 ( 0,40% ) | 5 Mio $ | 30.04.2024 |
Aktive Positionen von Christopher Mutz
| Unternehmen | Position | Beginn |
|---|---|---|
| ANI PHARMACEUTICALS, INC. | Corporate Officer/Principal | 17.02.2021 |
Ehemalige bekannte Positionen von Christopher Mutz
| Unternehmen | Position | Ende |
|---|---|---|
| ALEXION PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Ausbildung von Christopher Mutz
| University of Virginia | Undergraduate Degree |
| Johnson Graduate School of Management | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| ANI PHARMACEUTICALS, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
